Program
repaglinide
Also written as “Repaglinide”, “repaglinide and metformin combination tablet” and “Repaglinide/Metformin combination, Repaglinide, Metformin”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Obesity · Overweight · Gastrointestinal Stromal Tumors · Gout, led by 4 companies.
Drug pageRepaglinide: every studyAll 41 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novo Nordiskits history only | 130 open or running | phase 4since Jun 25, 2007 | Jun 25, 2007 | none ahead |
| Eli Lillyits history only | 30 open or running | phase 1since Jul 20, 2022 | Jul 20, 2022 | none ahead |
| Dalim BioTechits history only | 10 open or running | phase 1since Jan 29, 2013 | Jan 29, 2013 | none ahead |
| Merck | 10 open or running | phase 4since Oct 16, 2012 | Oct 16, 2012 | none ahead |
Also a collaborator on its studies: Basilea Pharmaceutica International.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Merck only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 16, 2012First study: phase 4 study in Diabetes Mellitus, Type 2First studyNCT01709305 · 5,570 enrolled
TargetBeta
“Sulfonylurea receptor 1, Kir6.2 blocker”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| mitigliniderule | Kissei Pharmaceutical | phase 4 | 9 |
Studies
The one study Merck leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01709305Diabetes Mellitus, Type 2 | 4 | Completed | Apr 17, 2015 | 5,570 |
How it is read
Names in the registry
- “Repaglinide”, 15 entries
- “repaglinide”, 13 entries
- “repaglinide and metformin combination tablet”, 2 entries
- “Repaglinide/Metformin combination, Repaglinide, Metformin”, 2 entries
- “repaglinide 0.5 mg tablet”, 1 entry
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 15 studies
- Obesity, 1 study
- Overweight, 1 study
- Gastrointestinal Stromal Tumors, 1 study
- Gout, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.